Personalization of Therapy for MDS: The Role of Biology, Risk Stratification, and Evolving Therapies

This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize the role of prognostic factors and prognostic scoring systems utilized in MDS
  • Discuss the current approaches to diagnostic evaluation, risk assessment, risk-adapted therapy, and supportive care needs for patients with MDS
  • Review recent clinical trial data with new combinations or investigational agents in MDS
Additional information
Supporters: 

Supported by educational grants from Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; and sanofi-aventis U.S.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.78 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
11/09/2012
Course expires: 
11/09/2013
Cost:
$0.00

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center

Available Credit

  • 0.75 Participation
  • 0.78 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Accreditation Period

Course opens: 
11/09/2012
Course expires: 
11/09/2013

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing